INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastases

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

November 1, 2027

Study Completion Date

November 1, 2028

Conditions
Colorectal Cancer Metastatic
Interventions
DRUG

Nelitolimod

Nelitolimod drug product is a clear to slightly opalescent, colorless to pale yellow solution free of visible particles and is supplied by TriSalus to the study sites in single-use vials. One vial is to be used per patient, and each vial should be discarded immediately after use.

Trial Locations (1)

11042

RJ Zuckerberg, Lake Success

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Northwell Health

OTHER